Concepedia

Vaximm (Germany)

V(

Statistics

Publications

16

Citations

912

Authors

2

Location

Mannheim, Germany

Vaximm (Germany) is a company institution in Mannheim, Germany.

Publications

16

Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial

Friedrich H. Schmitz-Winnenthal, Nicolas Hohmann, Andreas G. Niethammer et al. · OncoImmunology · 2015 · 72 citations · Full text

A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer

Friedrich H. Schmitz-Winnenthal, Nicolas Hohmann, Thomas Schmidt et al. · OncoImmunology · 2017 · 71 citations · Full text

Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer

Andreas G. Niethammer, Heinz Lubenau, Gerd Mikus et al. · BMC Cancer · 2012 · 57 citations · Full text

VXM01 phase I study in patients with progressive glioblastoma: Final results.

Wolfgang Wick, Antje Wick, Felix Sahm et al. · Journal of Clinical Oncology · 2018 · 16 citations

1–4 of 16

Authors

2

1–2 of 2